Beyond Air Announces Preclinical Data On Role Of Nitric Oxide In Autism Spectrum Disorder; Data To Be Presented At The 2023 International Society Of Neurochemistry And The European Society Of Neurochemistry Meeting In Portugal
Portfolio Pulse from Benzinga Newsdesk
Beyond Air, Inc. (NASDAQ:XAIR) announced the presentation of data supporting the ongoing preclinical development of selective neuronal nitric oxide synthase (nNOS) inhibitors for the treatment of Autism Spectrum Disorder (ASD). The data, to be presented at the 2023 International Society of Neurochemistry and the European Society of Neurochemistry meeting in Portugal, shows that inhibition of nitric oxide (NO) production may reverse ASD phenotypes. The company plans to advance its selective nNOS inhibitors into a first-in-human study in 2025.
August 07, 2023 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Beyond Air's announcement of promising preclinical data for its nNOS inhibitors for ASD treatment could potentially boost investor confidence and positively impact its stock price.
The announcement of promising preclinical data is a positive development for Beyond Air. This could potentially attract more investors, leading to an increase in demand for the company's stock and a rise in its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100